LOTEMAX

Peak

loteprednol etabonate

NDAOPHTHALMICGEL
Approved
Sep 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16

Mechanism of Action

healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid…

Clinical Trials (5)

NCT03531697Phase 1Completed

Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery

Started Apr 2018
381 enrolled
Inflammation Following Ocular Surgery
NCT02208297Phase 3Completed

Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Started Sep 2014
326 enrolled
InflammationPainCataract
NCT02322528N/ACompleted

Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

Started Apr 2014
10 enrolled
Sjogren's Disease
NCT01817582Phase 2Completed

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Started May 2013
102 enrolled
Keratoconjunctivitis Sicca
NCT01736527Phase 1Completed

Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

Started Jan 2013
12 enrolled
Pharmacokinetics